Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”
Executive Summary
Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy